A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU)
Latest Information Update: 11 Jan 2022
At a glance
- Drugs Fenebrutinib (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Sponsors Genentech
- 14 Feb 2020 Status changed from discontinued to completed.
- 19 Nov 2019 Status changed from recruiting to discontinued.
- 02 May 2019 Planned End Date changed from 23 Jan 2019 to 21 Dec 2019.